Page 3 - Revascularization Device News Today

Penumbra (NYSE:PEN – Get Free Report) and Quipt Home Medical (NASDAQ:QIPT – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, institutional ownership and earnings. Analyst Ratings This is a summary of recent […]

New York State Teachers Retirement System increased its holdings in shares of Penumbra, Inc. (NYSE:PEN – Free Report) by 1.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 36,036 shares of the company’s stock after purchasing an additional 345 […]

Congress Asset Management Co. MA lessened its position in shares of Penumbra, Inc. (NYSE:PEN – Free Report) by 13.3% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,257 shares of the company’s stock after selling 1,115 shares during the quarter. Congress Asset Management […]

Penumbra (NYSE:PEN – Get Free Report) and Sensus Healthcare (NASDAQ:SRTS – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, earnings, institutional ownership, risk and valuation. Insider & Institutional Ownership 88.2% of Penumbra shares are […]

Penumbra, Inc. (NYSE:PEN – Get Free Report) Director Harpreet Grewal sold 170 shares of the business’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $240.99, for a total value of $40,968.30. Following the completion of the sale, the director now owns 9,150 shares in the company, […]

Penumbra (NYSE:PEN – Get Free Report) had its price objective dropped by investment analysts at Citigroup from $390.00 to $320.00 in a research report issued to clients and investors on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Citigroup’s price objective indicates a potential upside of 35.08% from the company’s […]

Penumbra, Inc. (NYSE:PEN – Get Free Report) Director Don W. Kassing sold 444 shares of the stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $288.66, for a total value of $128,165.04. Following the transaction, the director now directly owns 1,458 shares of the company’s […]

Abbot Financial Management Inc. lowered its stake in Penumbra, Inc. (NYSE:PEN – Free Report) by 20.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 973 shares of the company’s stock after selling 246 shares during the period. Abbot Financial Management Inc.’s […]

FORA Capital LLC lowered its stake in shares of Penumbra, Inc. (NYSE:PEN – Free Report) by 2.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,602 shares of the company’s stock after selling 134 shares during the quarter. […]

Harvest Fund Management Co. Ltd increased its position in shares of Penumbra, Inc. (NYSE:PEN – Free Report) by 823.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 840 shares of the company’s stock after acquiring an additional 749 shares during the quarter. Harvest […]